Introduction of trimethoprim: a mixed blessing.
Trimethoprim recently has been released by the Food and Drug Administration (FDA) exclusively for the treatment of acute symptomatic uncomplicated bacterial urinary tract infections. The compound compares favorably with alternative standard agents, such as ampicillin and cephalexin, for the therapy of women with acute symptomatic urinary tract infections caused by Escherichia coli. Trimethoprim should not be prescribed for the pregnant woman. Indiscriminate administration of the drug could foster the emergence of strains resistant to trimethoprim and trimethoprim-sulfamethoxazole. Trimethoprim has not been approved by the FDA for the treatment of recurrent, bacterial urinary tract infections.
D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D014295:Trimethoprim